Latest Market Expansion News

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Zip Co Limited has posted record-breaking second quarter results for FY25, driven by exceptional holiday trading and robust growth in the US and ANZ markets. The company reported a 24.8% increase in Total Transaction Volume and a 50.2% rise in cash EBTDA.

RMA Global Limited has reported its first cash flow positive quarter since listing, alongside a 9% revenue increase driven by strong US and ANZ market performance and the strategic acquisition of Curated Social.

MyEco Group Ltd has reported a robust 32% increase in sustainable product sales for Q2 FY25, driven by a remarkable 156% jump in MyEco branded product sales. Despite negative operating cash flow due to inventory build-up, the company is poised for continued growth in the second half of the fiscal year.

Lark Distilling Co. Ltd reported a 7% increase in net sales revenue for Q2FY25, driven by strong growth in direct-to-consumer, global travel retail, and export channels despite domestic B2B challenges. The company is advancing its brand restage and maintaining solid cash reserves.

Change Financial Limited reported a robust Q2 FY25 with revenue surging 53% year-on-year, driven by its expanding PaaS platform, while strategically exiting its loss-making US operations to sharpen focus on Australia and New Zealand.

Alcidion Group Limited reported robust Q2 FY25 sales of $13.1 million and improved cash flow, reinforcing its forecast to achieve EBITDA and cashflow positivity by the end of FY25.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.

First Graphene has secured an additional AUD$404,300 R&D tax rebate for significant manufacturing process improvements at its Henderson facility, complementing a recent AUD$166,000 rebate from UK-based research efforts.

Nuchev Limited has reported its first positive operating cashflow quarter alongside a 65% increase in revenue for the first half of FY25, driven by strong sales growth and the bWellness acquisition.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.

ReNerve Limited has reported a remarkable 260% increase in quarterly sales following its successful IPO, alongside strategic distribution deals in Hong Kong and the Middle East. The company is poised for further growth with upcoming clinical data and product developments.